Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)

NCT07472491 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT07472491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07472491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)
Lead sponsor
GE Healthcare
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 1, 2026
Completion date
November 30, 2027
Enrollment
640 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

known or highly suspected body (excluding cns) lesion, known or highly suspected central nervous system (cns) lesion